The University of Virginia is conducting a clinical research study for adults ages 18 and over who have advanced Merkel cell skin cancer who have progressed on anti PD-(L) 1 therapy. The purpose of this study is to see is to compare the treatment of M1774 plus avelumab with M1774 alone. M1774 or the combination of M1774 plus avelumab could shrink your cancer or prevent it from returning. This is a randomized study, so you will be put into a group by chance. You will have an equal chance of being in Group 1 or Group 2:
Group 1 – If you are in group 1, you will receive M1774 as capsules that you take by mouth once a day for 14 days. Each cycle will last for 21 days, and you will receive the therapy until your cancer progresses or the doctor decides to take you off treatment. Avelumab may be added if your cancer progresses.
Group 2 – If you are in group 2, you will receive both avelumab and M1774. You will receive M1774 as capsules that you take by mouth once a day, for 14 out of 21 days. You will also receive avelumab through a vein in the arm the first day of each cycle. Each cycle lasts 21 days, and you will receive therapy until your cancer progresses or the doctor decides to take you off treatment.
After you stop study treatment, you will be followed up with every 6 months for 2 years to see how you are doing.
You and/or your insurance provider will not have to pay for exams, tests, and procedures done for research purposes only or that are covered by the study.
Additional information can be found here: https://clinicaltrials.gov/study/NCT05947500
No Compensation